Background With substantial progress made toward polio eradication, developing the appropriate strategy for discontinuing global oral poliovirus vaccine (OPV) after global eradication becomes increasingly important. At issue is the theoretical risk of independent circulation of potentially virulent OPV-derived strains. Because Cuba uses OPV only in mass campaigns, it represents an ideal site to assess vaccinederived poliovirus persistence.
Methods
Infants born after the 1997 biannual mass campaigns were evaluated for past (neutralizing antibody) or current (virus excretion) evidence of vaccine-derived poliovirus exposure. We obtained sera and/or stool specimens from 861 infants; a second serum from 218 infants.
Days (NID). Each NID round lasts approximately one week during February and April, targeting all children aged older than one month and younger than 3 years of age. 5 Because OPV is not available in the health system at any other time, it is possible to track the circulation of vaccine-derived viruses from a well-defined point (i.e. the NID).
If vaccine-derived poliovirus were to circulate in Cuba, it would most likely be found in the unvaccinated (therefore susceptible) infants born after the second round of the NID each year in April. In the current study, we used virus isolation and serological tests to assess unvaccinated infants for evidence of exposure to vaccine-derived poliovirus at 7-8 months following the 1997 NID.

Target sample size
We determined a target sample size of at least 900 children for this study. This would give a probability of more than 95% for detecting at least one shedding child if the true shedding rate was у0.5% and the participation rate was 80%, assuming that the probability of detecting the virus in the stool (specimen sensitivity) was 85%.
Selection of children
Study participants were enrolled in November-December 1997 through Havana's system of family physicians using a clustersampling scheme. The health care system of Havana comprises 81 health areas, each served by a clinic and staffed by a number of family physicians. Each family living in Havana is assigned a family physician, and each physician cares for an average of 3.4 children within the target age group. To select the children for this study, we randomly grouped the family physicians within each health area into clusters of 15 physicians each. Twenty-five clusters were then selected at random. To be eligible for the study, participants had to have been under the care of a family physician selected by the sampling procedure and either have been born after the April 1997 NID or be younger than 30 days (the lower age limit for vaccination) at the time of the NID. Infants whose age could not be determined were excluded. The selected family physicians targeted for enrolment all eligible infants under their care.
Sample collection
Our study design specified that a stool and serum specimen be collected from each study participant. To identify stable or declining antibody titres, a second serum sample was to be collected 6-8 weeks after the first serum and prior to the initiation of the 1998 NID (scheduled for the last week of January 1998) from children with detectable neutralizing antibodies in the first sample. After 10 December 1997 we collected only stool specimens and not sera because it would not have been possible to collect a second serum at the appropriate interval prior to the 1998 NID. Written informed consent was obtained from parents or guardians of study participants prior to administering the questionnaire and collecting the samples. In all, 8-10 g of stool were collected in an appropriate vessel and a lancet was used to obtain 0.5 ml of blood through a heel stick procedure. All stool and serum samples were tested at the Pedro Kouri Institute for Tropical Medicine in Havana.
Isolation and identification of poliovirus in stools
Isolation of virus was done according to the WHO recommended methods with the following modifications. 8 A 20% suspension was made of each stool sample using PBS (phosphate buffered saline) with antibiotics. The samples were clarified by centrifugation at 10 000 revolutions per minute in an Eppendorf centrifuge. The supernatant was stored in a freezer at -20°C until inoculation onto rhabdomyosarcoma (RD) and L20b cell lines using 0.2 ml of the supernatant. The tubes were incubated at 37°C and examined 24 hours later. Those that showed cytopathic effect (CPE) were frozen and thawed for passage to new cell tubes. The total observation time was 12 days before a sample was determined to be negative. In those tubes where CPE appeared in the L20b cells, identification was made by neutralization using the Lim-Benyesh-Melnick serum pools for the identification of poliovirus. Because of the lower sensitivity of the L20b cells, those samples that showed CPE only in RD cells were passed to the L20b cells. If the CPE persisted, identification proceeded in the manner described previously. Isolates that appeared to be a non-polio enterovirus were not further typed.
Determination of neutralizing antibodies
Neutralizing antibodies were determined by the method recommended by WHO. 8 Microneutralization was done on microtitre plates using twofold serial dilutions of sera beginning with 1:8. At each dilution, 25 µl of diluted serum was mixed with 25 µl of medium (Eagle MEM) containing 100 TCID50 (32-320) of Sabin poliovirus type 1, type 2, or type 3. The virus-serum mixture was incubated for 4 hours at 37°C in an atmosphere of 5% CO 2 . Then 100 µl of Hep-2 Cincinnati cell suspension (200 000 cells/ml) were added and the mixture incubated as before for 5 days. Each serum was tested in triplicate. Each test batch was accompanied by the following controls: cell control, serum toxicity control, virus dose and titration controls using an in-house reference serum validated against the international standard. To further characterize the antibodies, study participants having neutralizing antibodies at a titre of at least 1:8 to any of the three poliovirus serotypes were re-tested with a second serum drawn approximately 6-8 weeks after the initial sample.
Results
Study participation
Of 864 infants enrolled, 3 were later excluded for failure to meet the age criteria for inclusion ( Figure 1 ). Serum and stool were obtained from 739 and serum only from 23 infants between 30 November and 10 December 1997 (n = 762). Reasons for not obtaining a stool sample in these 23 included failure of the parent or guardian to bring a stool sample and loss to follow-up. Between 11 December and 31 December 1997, stool samples were obtained from an additional 99 infants (n = 838).
Stool survey
The analysis of the stool survey is based on the 838 infants from whom stools were obtained. Study participants ranged in age from newborn to 8 months (median: 3 months). No poliovirus was isolated from any study participant, giving an upper 95% confidence limit for the percentage shedding of 0.42%, assuming a specimen sensitivity of 85%. 9 Non-polio enteroviruses were isolated from 170 (20.3%) of the stool samples.
Serological survey
Serological results were available from 762 study participants. These infants ranged in age from newborn to 8 months, with a median age of 3 months. The age distributions were similar across health areas included in the study. From the screening of the initial serum sample at a dilution of 1:8, 252 (33.1%) of the 762 children were positive for neutralizing antibody to at least one poliovirus serotype ( Table 1 ). The highest rates were for type 2 (25.3%), followed by type 1 (14.8%) and type 3 (12.3%). In general, titres were inversely correlated with age. Also, the percentage positive to at least one serotype declined with age from 73.9% among the 46 infants under one month of age to 0% among the 14 infants aged 7 or 8 months. Because we had expected to find sustained seropositivity in infants born immediately after the NID, we further analysed this group (n = 14). 10 Compared with younger infants, these children were less likely to have other siblings in the household ( Of the 252 infants whose first sample was positive for neutralizing antibodies to poliovirus, we were able to collect a second sample from 218 (86.5%). The interval between the first and second samples ranged from 38 to 63 days (median VACCINE-DERIVED POLIOVIRUS CIRCULATION 1031 Figure 1 Schematic representation of study enrolment and specimen collection 51 days). During this interval, the neutralizing antibody titres of all 218 infants fell ( Figure 2 ). Among those whose initial titre was 1:32 or higher, all but one fell by at least 50%. The one exception was a one-month-old infant whose initial neutralization titres against both types 1 and 2 were 1:54; these subsequently declined modestly to 1:45. The interval between the first and second serum for this infant was 38 days, the shortest in the range of intervals and probably the reason for the modest decline. One 4-month old infant had an unusually high initial antibody titre to poliovirus type 3, 1:1211; this specimen was retested with a comparable result. By the second serum collected 53 days later, the titre had fallen to an undetectable level (also undetectable on repeat testing of the second serum). This infant was revisited, found to be healthy and did not have a history of receiving immune globulin.
The serological component of our study reflected 2419 personmonths of potential exposure among infants born beyond the immediate 3-month (post-NID) limit suggested by earlier studies. The absence of serological evidence for poliovirus infection corresponds to an exact upper 90% confidence bound of 4.4 infections/100 000/month within this age group based on the Poisson distribution.
Discussion
Our investigation provides compelling evidence that vaccinederived poliovirus does not persist for an extended period following the national mass vaccination campaigns with OPV in Havana. Single serum collection and viral isolation have been used separately by previous investigators and provided some evidence of limited circulation of vaccine-derived poliovirus (i.e. during 3 months following NID). [10] [11] [12] [13] [14] However, our study is unique in concurrently sampling stool specimens and paired sera from a large, susceptible, infant population. Paired sera allowed the determination that positive serology represented maternal antibodies, not exposure to vaccine virus. In addition, we found no serological evidence of virus exposure during 2419 person-months of risk beyond the 3-month period immediately following the NID.
The finding that all positive neutralizing antibodies in the first serum declined in the second serum sample, together with the age prevalence and magnitudes of these titre declines are consistent with their being of maternal origin rather than from poliovirus exposure. As expected, younger infants had the highest titres while older infants, born closer to the time of the NID, had the lowest titres. If the antibodies had resulted from exposure to vaccine virus, their titres would have been higher initially and remained high over the short interval between serum samples. These serological findings combined with the absence of poliovirus in any of the 838 stool samples provide powerful evidence of exceedingly low, if not absent, vaccine virus circulation.
Results of other studies indicate that circulation of vaccinederived polioviruses in temperate countries may be limited in time. In 1960 in Hungary, stool samples were obtained from 2017 children aged 3-23 months, approximately 4 months after the mass OPV campaigns; no polioviruses were isolated. 12 Data from the Netherlands, a country that changed from using OPV to using inactivated polio vaccine exclusively in their routine programme, demonstrated that almost all vaccine-derived 
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strains isolated in diagnostic laboratories could be linked to importation, not persistent indigenous circulation. 13 Also, recent molecular studies of vaccine viruses isolated from cases of acute flaccid paralysis in Brazil show little genetic drift, suggesting limited transmission. 14 In a 1992 study performed by us, we found serological evidence suggestive of rapidly disappearing vaccine strains during the 1-2 months immediately after the NID. 7 In the present study, we failed to detect this expected post-NID vaccine virus circulation. A potential explanation for this finding is that the 1992 mass campaigns targeted an additional age cohort (36-48 month olds) not targeted by the 1997 campaigns, thereby introducing more vaccine virus into the population. Alternatively, this finding may reflect the small sample (n = 14) of study participants potentially exposed to circulating vaccine virus immediately following the NID. We are not certain why so few 7-8 month olds participated in our study. It is possible that this age group was a less captive audience, seen less frequently by their family physicans relative to their younger 0-6-month-old counterparts.
Our study was done in an urban setting. It is likely, however, that the same result would have been found in rural Cuba where the lower population density, high vaccination coverage, and comparable sanitation are at least as inhospitable to vaccine virus circulation. Because Havana has relatively better sanitation and hygiene than may be found in cities in other developing countries, generalization of our findings to other countries may be limited. Furthermore, Cuba's excellent vaccine coverage has resulted in high levels of immunity throughout the population. In countries with less extensive vaccine coverage over the years, susceptible people in older age groups may contribute substantially to sustaining transmission.
In addition to providing data regarding the question of 'if' polio vaccination can stop, Cuba may be providing a clue regarding 'how' it should be discontinued. A strategy of maximizing population immunity followed by simultaneous OPV cessation (as occurs yearly after NID in Cuba) may create the conditions, during a discrete period of time, that favour rapid termination of vaccine virus circulation. It is possible that a similar scenario could be recreated worldwide, through implementation of a Global Immunization Day (GID), immediately followed by simultaneous global cessation of routine OPV. Although the logistics and the political challenges of a co-ordinated GID are formidable, there are reasons for optimism. Highly successful regional immunization days, involving tens of millions of children in dozens of countries in the European and South East Asian Regions of WHO, have already been implemented. 15, 16 In addition, the enthusiasm created by the successful completion of the polio eradication initiative may have favourable political implications for a co-ordinated strategy for OPV cessation.
Several additional studies should be initiated to answer important questions and further clarify possible global 'stop vaccination strategies'. The needed studies include (1) replication of the Cuban study in populations living in tropical areas with poorer sanitation and lower vaccination coverage; (2) assessment of the role played by children not typically targeted by the NID (5-15 year olds) in the transmission of vaccine-derived virus; (3) evaluation of vaccine-derived virus circulation in countries that have recently changed from an OPV to an IPV schedule; and (4) continued evaluation of individuals with immunodeficiencies that put them at risk for prolonged excretion of poliovirus both in industrialized and developing countries. 17, 18 The achievement of global polio eradication is expected by the end of 2002, with certification that polio has been eradicated in 2005. A scientifically sound strategy to discontinue all oral polio vaccination will not only eliminate the rare cases of vaccineassociated polio caused directly by the vaccine, but also lessen the possibility that vaccine strains will persist in the posteradication era. Our investigation in Cuba strengthens the scientific foundation for developing this strategy.
In this issue of the International Journal of Epidemiology, Mas Lago et al. 1 report the disappearance of oral polio vaccine (OPV) strains from Cuba following a national vaccination campaign, and infer from their results that OPV could be safely discontinued after polio eradication without fear that revertant viruses would continue to circulate and cause polio.
The public health successes accomplished by Cuba with regard to polio and other vaccine-preventable diseases are admirable and deserving of praise. However, there are a number of reasons to hesitate before extrapolating the polio results to other countries.
First, the search for persistent virus was conducted in an age group not ideal for the purpose: infants less than 8 months. It seems unlikely that infants who do not walk and who have little direct contact with older children would acquire infection, even if there were still excretors in the community. Evidence for this objection is found in the authors' own data. They show an absence of seroconversion among these infants, despite the probability that some of them were exposed to siblings who excreted attenuated polio virus in the weeks after the national campaign.
With regard to the issue of continued circulation of these strains, tests in 1-3-year-old infants would have been more interesting.
Second, no search for poliovirus in sewage is reported here. Although Mas Lago et al. tested over 800 infants, persistent excretion may be even rarer, and the 800 infants presumably included none with B cell immunodeficiency. Sewage testing screens larger populations.
Third, the Cuban population is already highly immune to polio, which would limit the spread of excreted OPV strains. The recent outbreak reported from nearby Hispaniola, where a type 1 revertant became epidemic in a poorly vaccinated population, 2 and similar episodes in Egypt and China, 3 lead to the conclusion that attenuated strains will re-acquire neurovirulence if given the opportunity for multiple passages in the human intestine.
Thus, although the data from Cuba are encouraging for that nation, and perhaps for other countries with reasonably high hygiene and public health infrastructure, they do not allow us to conclude that abrupt discontinuation of OPV, without other measures, will avoid resurrection of paralytic polio due to vaccine strains. More studies are needed before this possibly dangerous strategy, which will allow rapid accumulation of susceptibles in the possible presence of virulent virus, is adopted.
